Owen A. O’Connor, Chief Scientific Officer at TG Therapeutics, describes the phase 2 UNITY-NHL study, the results of which led to the FDA’s approval of umbralisib.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
